William D Travis

List of Publications by Year
in descending order

302 papers	66,485 citations	905 116 h-index	784 248 g-index
313 all docs	313 docs citations	313 times ranked	41582 citing authors

#	Article	IF	Citations
1	International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. Journal of Thoracic Oncology, 2011, 6, 244-285.	1.1	4,127
2	The 2015 World Health Organization Classification of Lung Tumors. Journal of Thoracic Oncology, 2015, 10, 1243-1260.	1.1	3,313
3	The IASLC Lung Cancer Staging Project: Proposals forÂRevision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 39-51.	1.1	3,162
4	An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 733-748.	5.6	3,134
5	Somatic mutations affect key pathways in lung adenocarcinoma. Nature, 2008, 455, 1069-1075.	27.8	2,694
6	Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2018, 198, e44-e68.	5.6	2,678
7	Comprehensive genomic profiles of small cell lung cancer. Nature, 2015, 524, 47-53.	27.8	1,634
8	Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. Radiology, 2017, 284, 228-243.	7.3	1,587
9	Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. Journal of Thoracic Oncology, 2015, 10, 1240-1242.	1.1	1,301
10	Characterizing the cancer genome in lung adenocarcinoma. Nature, 2007, 450, 893-898.	27.8	1,020
11	Gene expressionâ€“based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nature Medicine, 2008, 14, 822-827.	30.7	1,015
12	Recommendations for the Management of Subsolid Pulmonary Nodules Detected at CT: A Statement from the Fleischner Society. Radiology, 2013, 266, 304-317.	7.3	891
13	Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Modern Pathology, 2011, 24, 653-664.	5.5	866
14	Neuroendocrine Tumors of the Lung With Proposed Criteria for Large-Cell Neuroendocrine Carcinoma. American Journal of Surgical Pathology, 1991, 15, 529-553.	3.7	855
15	Survival Analysis of 200 Pulmonary Neuroendocrine Tumors With Clarification of Criteria for Atypical Carcinoid and Its Separation From Typical Carcinoid. American Journal of Surgical Pathology, 1998, 22, 934-944.	3.7	774
16	Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respiratory Medicine,the, 2018, 6, 138-153.	10.7	739
17	A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Modern Pathology, 2018, 31, 1770-1786.	5.5	739
18	The IASLC Lung Cancer Staging Project: Proposals for the Revision of the T Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 593-602.	1.1	658

#	Article	IF	Citations
19	Lung cancer. Cancer, 1995, 75, 191-202.	4.1	628
20	The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 990-1003.	1.1	628
21	Idiopathic Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 904-910.	5.6	574
22	The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 1204-1223.	1.1	530
23	Idiopathic Nonspecific Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1338-1347.	5.6	528
24	Idiopathic Nonspecific Interstitial Pneumonia: Prognostic Significance of Cellular and Fibrosing Patterns. American Journal of Surgical Pathology, 2000, 24, 19.	3.7	523
25	Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. Archives of Pathology and Laboratory Medicine, 2018, 142, 89-108.	2.5	461
26	New Pathologic Classification of Lung Cancer: Relevance for Clinical Practice and Clinical Trials. Journal of Clinical Oncology, 2013, 31, 992-1001.	1.6	458
27	International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: International Multidisciplinary Classification of Lung Adenocarcinoma: Executive Summary. Proceedings of the American Thoracic Society, 2011, 8, 381-385.	3.5	451
28	EWSR1â€POU5F1 fusion in soft tissue myoepithelial tumors. A molecular analysis of sixtyâ€six cases, including soft tissue, bone, and visceral lesions, showing common involvement of the EWSR1 gene. Genes Chromosomes and Cancer, 2010, 49, 1114-1124.	2.8	443
29	Pathology of Lung Cancer. Clinics in Chest Medicine, 2011, 32, 669-692.	2.1	436
30	A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Science Translational Medicine, 2015, 7, 302ra136.	12.4	436
31	Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 412-441.	4.9	432
32	The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. Journal of Thoracic Oncology, 2022, 17, 362-387.	1.1	429
33	Tumor Spread through Air Spaces is an Important Pattern of Invasion and Impacts the Frequency and Location of Recurrences after Limited Resection for Small Stage I Lung Adenocarcinomas. Journal of Thoracic Oncology, 2015, 10, 806-814.	1.1	428
34	Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncology, The, 2014, 15, e42-e50.	10.7	427
35	Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2012 Update of the Consensus Statement from the International Mesothelioma Interest Group. Archives of Pathology and Laboratory Medicine, 2013, 137, 647-667.	2.5	422
36	Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discovery, 2018, 8, 1548-1565.	9.4	422

#	Article	IF	Citations
37	Small Cell Lung Carcinoma (SCLC). American Journal of Surgical Pathology, 2002, 26, 1184-1197.	3.7	379
38	Validation of the IASLC/ATS/ERS Lung Adenocarcinoma Classification for Prognosis and Association with EGFR and KRAS Gene Mutations: Analysis of 440 Japanese Patients. Journal of Thoracic Oncology, 2013, 8, 52-61.	1.1	374
39	Pulmonary Pathologic Findings of Fatal 2009 Pandemic Influenza A/H1N1 Viral Infections. Archives of Pathology and Laboratory Medicine, 2010, 134, 235-243.	2.5	372
40	Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore. Human Pathology, 2003, 34, 743-748.	2.0	369
41	Diagnosis of Lung Cancer in Small Biopsies and Cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification. Archives of Pathology and Laboratory Medicine, 2013, 137, 668-684.	2.5	359
42	Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations Between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis. American Journal of Surgical Pathology, 2008, 32, 810-827.	3.7	352
43	Pleomorphic (spindle/giant cell) carcinoma of the lung. A clinicopathologic correlation of 78 cases. Cancer, 1994, 73, 2936-2945.	4.1	351
44	p40 (Î”Np63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Modern Pathology, 2012, 25, 405-415.	5.5	343
45	Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations. Clinical Cancer Research, 2012, 18, 1167-1176.	7.0	342
46	Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinomaâ€“like and Nonâ€“Small Cell Carcinomaâ€“like Subsets. Clinical Cancer Research, 2016, 22, 3618-3629.	7.0	342
47	The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage GroupingsÂin the Eighth Edition of the TNM Classification of LungÂCancer. Journal of Thoracic Oncology, 2017, 12, 1109-1121.	1.1	342
48	The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 300-311.	1.1	338
49	A Clinicopathologic Study of 100 Cases of Pulmonary Sclerosing Hemangioma With Immunohistochemical Studies. American Journal of Surgical Pathology, 2000, 24, 906-916.	3.7	321
50	Classification of Proliferative Pulmonary Lesions of the Mouse. Cancer Research, 2004, 64, 2307-2316.	0.9	313
51	Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Modern Pathology, 2011, 24, 1348-1359.	5.5	299
52	A Grading System of Lung Adenocarcinomas Based on Histologic Pattern is Predictive of Disease Recurrence in Stage I Tumors. American Journal of Surgical Pathology, 2010, 34, 1155-1162.	3.7	295
53	A Clinicopathologic Study of 34 Cases of Diffuse Pulmonary Hemorrhage with Lung Biopsy Confirmation. American Journal of Surgical Pathology, 1990, 14, 1112-1125.	3.7	289
54	Lung cancer â€" major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. Ca-A Cancer Journal for Clinicians, 2017, 67, 138-155.	329.8	283

#	Article	IF	Citations
55	Physiology Is a Stronger Predictor of Survival than Pathology in Fibrotic Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 639-644.	5.6	270
56	Evolving Concepts in the Pathology and Computed Tomography Imaging of Lung Adenocarcinoma and Bronchioloalveolar Carcinoma. Journal of Clinical Oncology, 2005, 23, 3279-3287.	1.6	264
57	The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification. Journal of Thoracic Oncology, 2016, 11, 142-154.	1.1	256
58	Visceral Pleural Invasion: Pathologic Criteria and Use of Elastic Stains: Proposal for the 7th Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology, 2008, 3, 1384-1390.	1.1	255
59	The IASLC Lung Cancer Staging Project: Proposals for the Inclusion of Broncho-Pulmonary Carcinoid Tumors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology, 2008, 3, 1213-1223.	1.1	255
60	Impact of Micropapillary Histologic Subtype in Selecting Limited Resection vs Lobectomy for Lung Adenocarcinoma of 2cm or Smaller. Journal of the National Cancer Institute, 2013, 105, 1212-1220.	6.3	255
61	Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. Nature Communications, 2018, 9, 1048.	12.8	254
62	ITMIG Consensus Statement on the Use of the WHO Histological Classification of Thymoma and Thymic Carcinoma: Refined Definitions, Histological Criteria, and Reporting. Journal of Thoracic Oncology, 2014, 9, 596-611.	1.1	247
63	Reproducibility of neuroendocrine lung tumor classification. Human Pathology, 1998, 29, 272-279.	2.0	243
64	Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nature Communications, 2014, 5, 3518.	12.8	239
65	Comprehensive Histologic Assessment Helps to Differentiate Multiple Lung Primary Nonsmall Cell Carcinomas From Metastases. American Journal of Surgical Pathology, 2009, 33, 1752-1764.	3.7	234
66	SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization. Journal of Thoracic Oncology, 2020, 15, 1823-1835.	1.1	234
67	A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 1599-1610.	1.1	234
68	Suitability of Thoracic Cytology for New Therapeutic Paradigms in Non-small Cell Lung Carcinoma: High Accuracy of Tumor Subtyping and Feasibility of EGFR and KRAS Molecular Testing. Journal of Thoracic Oncology, 2011, 6, 451-458.	1.1	230
69	Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas. Modern Pathology, 2012, 25, S18-S30.	5.5	227
70	A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Antiâ€“PD-1 Agent Pembrolizumab. Cancer Discovery, 2021, 11, 2748-2763.	9.4	222
71	United States lung carcinoma incidence trends: Declining for most histologic types among males, increasing among females. Cancer, 1996, 77, 2464-2470.	4.1	215
72	Lung Cancer Screening. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 240-265.	4.9	215

#	Article	IF	Citations
73	Prognostic Significance of Adenocarcinoma In Situ, Minimally Invasive Adenocarcinoma, and Nonmucinous Lepidic Predominant Invasive Adenocarcinoma of the Lung in Patients With Stage I Disease. American Journal of Surgical Pathology, 2014, 38, 448-460.	3.7	214
74	Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 377-407.	1.1	212
75	The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 651-665.	1.1	211
76	Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. Modern Pathology, 2012, 25, 1574-1583.	5.5	206
77	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. Journal of Thoracic Oncology, 2020, 15, 709-740.	1.1	205
78	Clinical Impact of Immune Microenvironment in Stage I Lung Adenocarcinoma: Tumor Interleukin-12 Receptor Î²2 (IL-12RÎ²2), IL-7R, and Stromal FoxP3/CD3 Ratio Are Independent Predictors of Recurrence. Journal of Clinical Oncology, 2013, 31, 490-498.	1.6	203
79	Radiologic Implications of the 2011 Classification of Adenocarcinoma of the Lung. Radiology, 2013, 266, 62-71.	7.3	201
80	The IASLC Lung Cancer Staging Project: Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of NSCLC in the Forthcoming (Eighth) Edition of the TNM Classification of Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 1433-1446.	1.1	201
81	Solitary and multiple resected adenocarcinomas after CT screening for lung cancer: Histopathologic features and their prognostic implications. Lung Cancer, 2009, 64, 148-154.	2.0	195
82	Genetic changes in the spectrum of neuroendocrine lung tumors. , 1999, 85, 600-607.		193
83	US lung cancer trends by histologic type. Cancer, 2014, 120, 2883-2892.	4.1	193
84	Thymic carcinoma outcomes and prognosis: Results of an international analysis. Journal of Thoracic and Cardiovascular Surgery, 2015, 149, 95-101.e2.	0.8	190
85	The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification. Journal of Thoracic Oncology, 2016, 11, 639-650.	1.1	182
86	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 1409-1424.	1.1	182
87	Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival. Journal of Clinical Oncology, 2015, 33, 2877-2884.	1.6	181
88	Pathologic Diagnosis of Advanced Lung Cancer Based on Small Biopsies and Cytology: A Paradigm Shift. Journal of Thoracic Oncology, 2010, 5, 411-414.	1.1	172
89	SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas. Journal of Thoracic Oncology, 2020, 15, 231-247.	1.1	172
90	The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Application of TNM Staging Rules to Lung Cancer Presenting as Multiple Nodules with Ground Glass or Lepidic Features or a Pneumonic Type of Involvement in the Forthcoming Eighth Edition of the TNM Classification. Journal of Thoracic Oncology, 2016, 11, 666-680.	1.1	170

#	Article	IF	Citations
91	Lymphangioleiomyomatosis. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 1210-1212.	5.6	168
92	A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1249-1254.	5.6	166
93	Ki-67 Antigen in Lung Neuroendocrine Tumors: Unraveling a Role in Clinical Practice. Journal of Thoracic Oncology, 2014, 9, 273-284.	1.1	162
94	Lobectomy Is Associated with Better Outcomes than Sublobar Resection in Spread through Air Spaces (STAS)-Positive T1 Lung Adenocarcinoma: AÂPropensity Scoreâ€“Matched Analysis. Journal of Thoracic Oncology, 2019, 14, 87-98.	1.1	153
95	Genomic and Mutational Profiling to Assess Clonal Relationships Between Multiple Nonâ€“Small Cell Lung Cancers. Clinical Cancer Research, 2009, 15, 5184-5190.	7.0	151
96	Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker. Clinical Cancer Research, 2012, 18, 1138-1145.	7.0	151
97	The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung. Human Pathology, 2003, 34, 136-142.	2.0	149
98	A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. Modern Pathology, 2012, 25, 1117-1127.	5.5	148
99	A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma. Modern Pathology, 2012, 25, 260-271.	5.5	142
100	Overexpression of Phospho-eIF4E Is Associated with Survival through AKT Pathway in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2010, 16, 240-248.	7.0	141
101	Diagnosis of Lung Adenocarcinoma in Resected Specimens: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification. Archives of Pathology and Laboratory Medicine, 2013, 137, 685-705.	2.5	141
102	The Spectrum of Immunohistochemical Staining of Small-cell Lung Carcinoma in Specimens From Transbronchial and Open-lung Biopsies. American Journal of Clinical Pathology, 1994, 102, 406-414.	0.7	140
103	Pathological Diagnosis and Classification of Lung Cancer in Small Biopsies and Cytology: Strategic Management of Tissue for Molecular Testing. Seminars in Respiratory and Critical Care Medicine, 2011, 32, 022-031.	2.1	140
104	An Expression Signature as an Aid to the Histologic Classification of Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2016, 22, 4880-4889.	7.0	140
105	Spread through Air Spaces (STAS) Is an Independent Predictor of Recurrence and Lung Cancerâ€“Specific Death in Squamous Cell Carcinoma. Journal of Thoracic Oncology, 2017, 12, 223-234.	1.1	134
106	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 1818-1831.	1.1	133
107	Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal COVID-19. Science Translational Medicine, 2021, 13, eabj7790.	12.4	133
108	Associations Between Mutations and Histologic Patterns of Mucin in Lung Adenocarcinoma. American Journal of Surgical Pathology, 2014, 38, 1118-1127.	3.7	131

#	Article	IF	Citations
109	Pathologic characteristics of drug-induced lung disease. Clinics in Chest Medicine, 2004, 25, 37-45.	2.1	129
110	Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma. Clinical Cancer Research, 2014, 20, 1020-1028.	7.0	128
111	Thoracic Epithelioid Malignant Vascular Tumors. American Journal of Surgical Pathology, 2015, 39, 132-139.	3.7	128
112	Using frozen section to identify histological patterns in stage I lung adenocarcinoma of â‰¤3Âcm: accuracy and interobserver agreement. Histopathology, 2015, 66, 922-938.	2.9	127
113	Role for Activation of Matrix Metalloproteinases in the Pathogenesis of Pulmonary Lymphangioleiomyomatosis. Archives of Pathology and Laboratory Medicine, 2000, 124, 267-275.	2.5	127
114	Sarcomatoid Neoplasms of the Lung and Pleura. Archives of Pathology and Laboratory Medicine, 2010, 134, 1645-1658.	2.5	125
115	The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?. Journal of Thoracic Oncology, 2022, 17, 200-213.	1.1	124
116	A Practical Algorithmic Approach to the Diagnosis and Management of Solitary Pulmonary Nodules. Chest, 2013, 143, 825-839.	0.8	123
117	Subtyping of Non-small Cell Lung Carcinoma: A Comparison of Small Biopsy and Cytology Specimens. Journal of Thoracic Oncology, 2011, 6, 1849-1856.	1.1	121
118	The cribriform pattern identifies a subset of acinar predominant tumors with poor prognosis in patients with stage I lung adenocarcinoma: a conceptual proposal to classify cribriform predominant tumors as a distinct histologic subtype. Modern Pathology, 2014, 27, 690-700.	5.5	121
119	New Approaches to SCLC Therapy: From the Laboratory to the Clinic. Journal of Thoracic Oncology, 2020, 15, 520-540.	1.1	119
120	Peribronchiolar Metaplasia: A Common Histologic Lesion in Diffuse Lung Disease and a Rare Cause of Interstitial Lung Disease. American Journal of Surgical Pathology, 2005, 29, 948-954.	3.7	116
121	Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes. Clinical Lung Cancer, 2016, 17, e121-e129.	2.6	116
122	Predictors of Outcomes after Surgical Treatment of Synchronous Primary Lung Cancers. Journal of Thoracic Oncology, 2010, 5, 197-205.	1.1	115
123	Pathology and Diagnosis of Neuroendocrine Tumors. Thoracic Surgery Clinics, 2014, 24, 257-266.	1.0	114
124	The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases. Journal of Thoracic Oncology, 2017, 12, 334-346.	1.1	113
125	Hereditary Lung Cancer Syndrome Targets Never Smokers with Germline EGFR Gene T790M Mutations. Journal of Thoracic Oncology, 2014, 9, 456-463.	1.1	112
126	The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers. OncoImmunology, 2015, 4, e1009285.	4.6	112

#	Article	IF	Citations
127	Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Nonâ€“Small-Cell Lung Cancers. Journal of Thoracic Oncology, 2013, 8, 1084-1090.	1.1	111
128	Pleomorphic Epithelioid Diffuse Malignant Pleural Mesothelioma: A Clinicopathological Review and Conceptual Proposal to Reclassify as Biphasic or Sarcomatoid Mesothelioma. Journal of Thoracic Oncology, 2011, 6, 896-904.	1.1	110
129	Cystic Lung Diseases. Chest, 2016, 150, 945-965.	0.8	107
130	Development of the International Thymic Malignancy Interest Group International Database: An Unprecedented Resource for the Study of a Rare Group of Tumors. Journal of Thoracic Oncology, 2014, 9, 1573-1578.	1.1	106
131	EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. Journal of Thoracic Oncology, 2020, 15, 29-49.	1.1	106
132	Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria. Journal of Thoracic Oncology, 2006, 1, S13-S19.	1.1	106
133	Diagnosis and Evaluation of Hypersensitivity Pneumonitis. Chest, 2021, 160, e97-e156.	0.8	104
134	Comprehensive Pathological Analyses in Lung Squamous Cell Carcinoma: Single Cell Invasion, Nuclear Diameter, and Tumor Budding Are Independent Prognostic Factors for Worse Outcomes. Journal of Thoracic Oncology, 2014, 9, 1126-1139.	1.1	102
135	Lung Cancer Screening, Version 1.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 23-34.	4.9	102
136	American Thoracic Societyâ€“European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002. Radiographics, 2015, 35, 1849-1871.	3.3	102
137	The histopathology of Erdheimâ€“Chester disease: a comprehensive review of a molecularly characterized cohort. Modern Pathology, 2018, 31, 581-597.	5.5	102
138	The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 681-692.	1.1	101
139	The Comparative Pathology of Genetically Engineered Mouse Models for Neuroendocrine Carcinomas of the Lung. Journal of Thoracic Oncology, 2015, 10, 553-564.	1.1	100
140	Clinical significance of TTFâ€1 protein expression and TTFâ€1 gene amplification in lung adenocarcinoma. Journal of Cellular and Molecular Medicine, 2009, 13, 1977-1986.	3.6	98
141	Outcome of primary neuroendocrine tumors of the thymus: A joint analysis of the International Thymic Malignancy Interest Group and the European Society of Thoracic Surgeons databases. Journal of Thoracic and Cardiovascular Surgery, 2015, 149, 103-109.e2.	0.8	96
142	Clear Cell "Sugar" Tumor of the Lung: Association with Lymphangioleiomyomatosis and Multifocal Micronodular Pneumocyte Hyperplasia in a Patient with Tuberous Sclerosis. American Journal of Surgical Pathology, 1997, 21, 1242-1247.	3.7	96
143	Neoadjuvant and Adjuvant Chemotherapy in Resected Pulmonary Large Cell Neuroendocrine Carcinomas: A Single Institution Experience. Annals of Thoracic Surgery, 2011, 92, 1180-1187.	1.3	95
144	Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. Modern Pathology, 2013, 26, 511-522.	5.5	95

#	Article	IF	Citations
145	Lung tumours with neuroendocrine differentiation. European Journal of Cancer, 2009, 45, 251-266.	2.8	94
146	FDG-PET SUVmax Combined with IASLC/ATS/ERS Histologic Classification Improves the Prognostic Stratification of Patients with Stage I Lung Adenocarcinoma. Annals of Surgical Oncology, 2012, 19, 3598-3605.	1.5	93
147	Use of Epidermal Growth Factor Receptor/Kirsten Rat Sarcoma 2 Viral Oncogene Homolog Mutation Testing to Define Clonal Relationships Among Multiple Lung Adenocarcinomas. Chest, 2010, 137, 46-52.	0.8	92
148	Insights into pathogenesis of fatal COVIDâ€19 pneumonia from histopathology with immunohistochemical and viral RNA studies. Histopathology, 2020, 77, 915-925.	2.9	92
149	Bronchiolar Adenoma. American Journal of Surgical Pathology, 2018, 42, 1010-1026.	3.7	91
150	Lung Tumors With a Rhabdoid Phenotype. American Journal of Clinical Pathology, 1996, 105, 182-188.	0.7	88
151	Prognostic stratification of clinical and molecular epithelioid hemangioendothelioma subsets. Modern Pathology, 2020, 33, 591-602.	5.5	87
152	Lung cancer staging: a concise update. European Respiratory Journal, 2018, 51, 1800190.	6.7	84
153	The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2020, 15, 1844-1856.	1.1	83
154	Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma. Journal of Thoracic Oncology, 2019, 14, 482-493.	1.1	81
155	Progression to fibrosing diffuse alveolar damage in a series of 30 minimally invasive autopsies with COVIDâ€19 pneumonia in Wuhan, China. Histopathology, 2021, 78, 542-555.	2.9	79
156	The New IASLC-ATS-ERS Lung Adenocarcinoma Classification: What the Surgeon Should Know. Seminars in Thoracic and Cardiovascular Surgery, 2014, 26, 210-222.	0.6	76
157	Lung Cancer Pathology. Clinics in Chest Medicine, 2020, 41, 67-85.	2.1	73
158	Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria. Journal of Thoracic Oncology, 2006, 1, S13-S19.	1.1	71
159	Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients. Cancer Immunology, Immunotherapy, 2011, 60, 1721-1728.	4.2	70
160	Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study. Modern Pathology, 2018, 31, 598-606.	5.5	70
161	Initial Experience With Lung Cancer Resection After Treatment With T-Cell Checkpoint Inhibitors. Annals of Thoracic Surgery, 2017, 104, e217-e218.	1.3	69
162	Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach. Clinical Cancer Research, 2019, 25, 7113-7125.	7.0	69

#	Article	IF	Citations
163	MEN1 gene mutation analysis of high-grade neuroendocrine lung carcinoma. , 2000, 28, 58-65.		68
164	Cavitary Lung Diseases. Chest, 2018, 153, 1443-1465.	0.8	67
165	Recurrence of Pulmonary Carcinoid Tumors After Resection: Implications for Postoperative Surveillance. Annals of Thoracic Surgery, 2013, 96, 1156-1162.	1.3	66
166	Pathologic Findings of Lung Tumors Diagnosed on Baseline CT Screening. American Journal of Surgical Pathology, 2006, 30, 606-613.	3.7	65
167	Prognostic model of survival for typical bronchial carcinoid tumours: analysis of 1109 patients on behalf of the European Association of Thoracic Surgeons (ESTS) Neuroendocrine Tumours Working Group. European Journal of Cardio-thoracic Surgery, 2015, 48, 441-447.	1.4	65
168	V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma. Modern Pathology, 2020, 33, 303-311.	5.5	65
169	Hepatic involvement in mastocytosis: Clinicopathologic correlations in 41 cases. Hepatology, 1995, 22, 1163-1170.	7.3	64
170	International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification predicts occult lymph node metastasis in clinically mediastinal node-negative lung adenocarcinoma. European Journal of Cardio-thoracic Surgery, 2016, 49, e9-e15.	1.4	64
171	The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification. Journal of Thoracic Oncology, 2022, 17, 608-622.	1.1	64
172	Tumor genetics and survival of thymic neuroendocrine neoplasms: A multiâ€institutional clinicopathologic study. Genes Chromosomes and Cancer, 2014, 53, 738-749.	2.8	63
173	Reporting lung cancer pathology specimens. Impact of the anticipated 7th Edition TNM Classification based on recommendations of the IASLC Staging Committee. Histopathology, 2009, 54, 3-11.	2.9	62
174	Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements. Journal of Thoracic Oncology, 2019, 14, 825-834.	1.1	62
175	Reevaluation and Reclassification of Resected Lung Carcinomas Originally Diagnosed as Squamous Cell Carcinoma Using Immunohistochemical Analysis. American Journal of Surgical Pathology, 2015, 39, 1170-1180.	3.7	61
176	Counting mitoses: SI(ze) matters!. Modern Pathology, 2021, 34, 1651-1657.	5.5	61
177	Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices. Modern Pathology, 2019, 32, 1106-1122.	5.5	58
178	Standardized terminology and nomenclature for respiratory cytology: The <scp>P</scp>apanicolaou Society of Cytopathology guidelines. Diagnostic Cytopathology, 2016, 44, 399-409.	1.0	57
179	An ultrastructural study ofIn vivo interactions between lymphocytes and endothelial cells in the pathogenesis of the vascular leak syndrome induced by interleukin-2. Cancer, 1991, 68, 2169-2174.	4.1	55
180	Spread Through Air Spaces (STAS) Is Prognostic in Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung. Journal of Thoracic Oncology, 2019, 14, 1583-1593.	1.1	55

#	Article	IF	Citations
181	Three-Dimensional Histologic, Immunohistochemical, and Multiplex Immunofluorescence Analyses of Dynamic Vessel Co-Option of Spread Through Air Spaces in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2020, 15, 589-600.	1.1	55
182	Hematopathology of the Bone Marrow in Pediatric Cutaneous Mastocytosis: A Study of 17 Patients. American Journal of Clinical Pathology, 1989, 91, 558-562.	0.7	54
183	Validation of Interobserver Agreement in Lung Cancer Assessment: Hematoxylin-Eosin Diagnostic Reproducibility for Nonâ€“Small Cell Lung Cancer: The 2004 World Health Organization Classification and Therapeutically Relevant Subsets. Archives of Pathology and Laboratory Medicine, 2013, 137, 32-40.	2.5	54
184	Tumor Budding Correlates With the Protumor Immune Microenvironment and Is an Independent Prognostic Factor for Recurrence of Stage I Lung Adenocarcinoma. Chest, 2015, 148, 711-721.	0.8	53
185	Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society. Radiology, 2021, 298, 550-566.	7.3	53
186	Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors. Chest, 2021, 159, 1107-1125.	0.8	53
187	Comparison of outcomes between neuroendocrine thymic tumours and other subtypes of thymic carcinomas: a joint analysis of the European Society of Thoracic Surgeons and the International Thymic Malignancy Interest Group. European Journal of Cardio-thoracic Surgery, 2016, 50, 766-771.	1.4	52
188	KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma. American Journal of Surgical Pathology, 2016, 40, 1579-1590.	3.7	50
189	Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: napsin A expression and genomic alterations. Modern Pathology, 2018, 31, 111-121.	5.5	50
190	The IASLC Lung Cancer Staging Project: A Renewed Call to Participation. Journal of Thoracic Oncology, 2018, 13, 801-809.	1.1	49
191	Myocarditis or acute myocardial infarction associated with interleukin-2 therapy for cancer. Cancer, 1990, 66, 1513-1516.	4.1	47
192	Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase. Lung Cancer, 2014, 86, 237-240.	2.0	47
193	Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma. Journal of Thoracic Oncology, 2015, 10, 1301-1310.	1.1	47
194	Integrative Genomic Characterization Identifies Molecular Subtypes of Lung Carcinoids. Cancer Research, 2019, 79, 4339-4347.	0.9	47
195	Clinically Relevant Characterization of Lung Adenocarcinoma Subtypes Based on Cellular Pathways: An International Validation Study. PLoS ONE, 2010, 5, e11712.	2.5	47
196	A Combined Small Cell and Spindle Cell Carcinoma of the Lung. American Journal of Surgical Pathology, 1992, 16, 1108-1115.	3.7	45
197	Thyroid transcription factorâ€1 expression is an independent predictor of recurrence and correlates with the IASLC/ATS/ERS histologic classification in patients with stage I lung adenocarcinoma. Cancer, 2013, 119, 931-938.	4.1	45
198	Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes. Clinical Cancer Research, 2021, 27, 4066-4076.	7.0	45

#	Article	IF	Citations
199	Serum antiâ€”SSâ€B/La and IgA rheumatoid factor are markers of salivary gland disease activity in primary sjÃ¶gren's syndrome. Arthritis and Rheumatism, 1992, 35, 1368-1372.	6.7	44
200	Consistent copy number changes and recurrent <scp>PRKAR1A</scp> mutations distinguish <scp>M</scp>elanotic <scp>S</scp>chwannomas from <scp>M</scp>elanomas: <scp>SNP</scp>â€array and next generation sequencing analysis. Genes Chromosomes and Cancer, 2015, 54, 463-471.	2.8	44
201	Retroperitoneal germ cell tumors in childhood. A clinical and pathologic study of 11 cases. Cancer, 1985, 56, 602-608.	4.1	43
202	Histologic Subtype in Core Lung Biopsies of Early-Stage Lung Adenocarcinoma is a Prognostic Factor for Treatment Response and Failure Patterns After Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 97, 138-145.	0.8	43
203	Tumor Spread Through Air Spaces Is a Predictor of Occult Lymph Node Metastasis in Clinical Stage IA Lung Adenocarcinoma. Journal of Thoracic Oncology, 2020, 15, 792-802.	1.1	43
204	Classification of Lung Cancer. Seminars in Roentgenology, 2011, 46, 178-186.	0.6	42
205	Adaptive Neoadjuvant Chemotherapy Guided by 18 F-FDG PET in Resectable Nonâ€“Small Cell Lung Cancers: The NEOSCAN Trial. Journal of Thoracic Oncology, 2016, 11, 537-544.	1.1	42
206	Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas. Lung Cancer, 2017, 108, 205-211.	2.0	42
207	A comparison of the pathological, clinical and radiographical, features of cryptogenic organising pneumonia, acute fibrinous and organising pneumonia and granulomatous organising pneumonia. Journal of Clinical Pathology, 2015, 68, 441-447.	2.0	41
208	Procedure-Specific Risk Prediction for Recurrence in Patients Undergoing Lobectomy or Sublobar Resection for Small (â‰2 cm) Lung Adenocarcinoma: An International Cohort Analysis. Journal of Thoracic Oncology, 2019, 14, 72-86.	1.1	41
209	Ki 67 is an Independent Predictive Biomarker of Cancer Specific and Local Recurrence-Free Survival After Lung Tumor Ablation. Annals of Surgical Oncology, 2013, 20, 676-683.	1.5	40
210	Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center. Journal of Thoracic Oncology, 2020, 15, 1037-1053.	1.1	40
211	Clinicopathological features and the impact of the new TNM classification of malignant tumors in patients with pulmonary large cell neuroendocrine carcinoma. Molecular and Clinical Oncology, 2013, 1, 437-443.	1.0	39
212	Pulmonary Neuroendocrine Tumors: What (Little) Do We Know?. Journal of the National Comprehensive Cancer Network: JNCCN, 2006, 4, 623-630.	4.9	37
213	Visceral Pleural Invasion Does Not Affect Recurrence or Overall Survival Among Patients With Lung Adenocarcinoma â‰ 2 cm. Chest, 2013, 144, 1622-1631.	0.8	37
214	Hyperplasia of Type II Pneumocytes in Pulmonary Lymphangioleiomyomatosis. Archives of Pathology and Laboratory Medicine, 2000, 124, 1642-1648.	2.5	37
215	Smoking-related idiopathic interstitial pneumonia. European Respiratory Journal, 2014, 44, 594-602.	6.7	36
216	The Fake Fat Phenomenon in Organizing Pleuritis. American Journal of Surgical Pathology, 2011, 35, 1823-1829.	3.7	35

#	Article	IF	Citations
217	Expansion of the Concept of Micropapillary Adenocarcinoma to Include a Newly Recognized Filigree Pattern as Well as the Classical Pattern Based on 1468 Stage I Lung Adenocarcinomas. Journal of Thoracic Oncology, 2019, 14, 1948-1961.	1.1	35
218	Usual Interstitial Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2001, 22, 357-386.	2.1	34
219	Lung adenocarcinoma subtypes based on expression of human airway basal cell genes. European Respiratory Journal, 2013, 42, 1332-1344.	6.7	34
220	Reproducibility of Histopathological Diagnosis in Poorly Differentiated NSCLC: An International Multiobserver Study. Journal of Thoracic Oncology, 2014, 9, 1354-1362.	1.1	34
221	Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. Journal of Thoracic Oncology, 2006, 1, S13-9.	1.1	34
222	Aspiration Cytomorphology of Fetal Adenocarcinoma of the Lung. American Journal of Clinical Pathology, 2010, 134, 894-902.	0.7	33
223	Pathologic classification of adenocarcinoma of lung. Journal of Surgical Oncology, 2013, 108, 320-326.	1.7	33
224	Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung. Journal of Thoracic Oncology, 2018, 13, 205-217.	1.1	33
225	High SUVmax on FDG-PET Indicates Pleomorphic Subtype in Epithelioid Malignant Pleural Mesothelioma: Supportive Evidence to Reclassify Pleomorphic as Nonepithelioid Histology. Journal of Thoracic Oncology, 2012, 7, 1192-1197.	1.1	32
226	Predicting pulmonary adenocarcinoma outcome based on a cytology grading system. Cancer Cytopathology, 2012, 120, 35-43.	2.4	32
227	Implications of the Eighth Edition of the TNM Proposal: Invasive Versus Total Tumor Size for the T Descriptor in Pathologic Stage I-IIA Lung Adenocarcinoma. Journal of Thoracic Oncology, 2018, 13, 1919-1929.	1.1	32
228	A Report of Familial Carotid Body Tumors and Multiple Extra-Adrenal Pheochromocytomas. Journal of Urology, 1991, 145, 1040-1042.	0.4	31
229	Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1. Oncotarget, 2017, 8, 77872-77882.	1.8	31
230	Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 nonâ€“small cell lung cancer: A propensity-matched analysis. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, 743-753.e3.	0.8	30
231	What CT characteristics of lepidic predominant pattern lung adenocarcinomas correlate with invasiveness on pathology?. Lung Cancer, 2018, 118, 83-89.	2.0	27
232	Identification of Immunohistochemical Reagents for In Situ Protein Expression Analysis of Coronavirus-associated Changes in Human Tissues. Applied Immunohistochemistry and Molecular Morphology, 2021, 29, 5-12.	1.2	26
233	Pathologic and molecular features of screening low-dose computed tomography (LDCT)-detected lung cancer: A baseline and 2-year repeat study. Lung Cancer, 2008, 62, 202-214.	2.0	25
234	Histological grading in lung cancer: one system for all or separate systems for each histological type?. European Respiratory Journal, 2016, 47, 720-723.	6.7	25

#	Article	IF	Citations
235	Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset. Clinical Cancer Research, 2022, 28, 4702-4713.	7.0	25
236	Adjuvant chemotherapy for large-cell neuroendocrine lung carcinoma: results from the European Society for Thoracic Surgeons Lung Neuroendocrine Tumours Retrospective Database. European Journal of Cardio-thoracic Surgery, 2017, 52, 339-345.	1.4	24
237	Eighth Edition Staging of Thoracic Malignancies: Implications for the Reporting Pathologist. Archives of Pathology and Laboratory Medicine, 2018, 142, 645-661.	2.5	24
238	Histologic subtyping in pathologic stage I-IIA lung adenocarcinoma provides risk-based stratification for surveillance. Oncotarget, 2018, 9, 35742-35751.	1.8	24
239	Molecular Characterization of Peritoneal Mesotheliomas. Journal of Thoracic Oncology, 2022, 17, 455-460.	1.1	24
240	The International Association Study Lung Cancer (IASLC) Strategic Screening Advisory Committee (SSAC) Response to the USPSTF Recommendations. Journal of Thoracic Oncology, 2014, 9, 141-143.	1.1	23
241	Lung-only melanoma: UV mutational signature supports origin from occult cutaneous primaries and argues against the concept of primary pulmonary melanoma. Modern Pathology, 2020, 33, 2244-2255.	5.5	23
242	Invasive Mucinous Adenocarcinomas With Spatially Separate Lung Lesions: Analysis of Clonal Relationship by Comparative Molecular Profiling. Journal of Thoracic Oncology, 2021, 16, 1188-1199.	1.1	23
243	Title is missing!. , 2017, , .		22
244	Protocol for the Examination of Specimens From Patients With Primary Nonâ€“Small Cell Carcinoma, Small Cell Carcinoma, or Carcinoid Tumor of the Lung. Archives of Pathology and Laboratory Medicine, 2009, 133, 1552-1559.	2.5	22
245	Large No More: The Journey of Pulmonary Large Cell Carcinoma from Common to Rare Entity. Journal of Thoracic Oncology, 2019, 14, 1125-1127.	1.1	21
246	Nuclear estrogen receptor-Î± expression is an independent predictor of recurrence in male patients with pT1aN0 lung adenocarcinomas, and correlates with regulatory T-cell infiltration. Oncotarget, 2015, 6, 27505-27518.	1.8	21
247	Testing for Neuroendocrine Immunohistochemical Markers Should Not Be Performed in Poorly Differentiated NSCCs in the Absence of Neuroendocrine Morphologic Features according to the 2015 WHO Classification. Journal of Thoracic Oncology, 2016, 11, e26-e27.	1.1	19
248	Rapid EGFR Mutation Detection Using the Idylla Platform. Journal of Molecular Diagnostics, 2021, 23, 310-322.	2.8	19
249	Introduction to 2021 WHO Classification of Thoracic Tumors. Journal of Thoracic Oncology, 2022, 17, e1-e4.	1.1	19
250	Integration and Application of Clinical Practice Guidelines for the Diagnosis of Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis. Chest, 2022, 162, 614-629.	0.8	19
251	Carcinoma In Situ at the Bronchial Resection Margin: A Review. Journal of Thoracic Oncology, 2011, 6, 1617-1623.	1.1	18
252	Utility of Core Biopsy Specimen to Identify Histologic Subtype and Predict Outcome for Lung Adenocarcinoma. Annals of Thoracic Surgery, 2019, 108, 392-398.	1.3	18

#	Article	IF	Citations
253	BRMS1 Expression in Surgically Resected Lung Adenocarcinoma Predicts Future Metastases and IsÂAssociated with a Poor Prognosis. Journal of Thoracic Oncology, 2018, 13, 73-84.	1.1	17
254	Cell cycle progression score is a marker for five-year lung cancer-specific mortality risk in patients with resected stage I lung adenocarcinoma. Oncotarget, 2016, 7, 35241-35256.	1.8	17
255	Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway. Cell Reports, 2021, 34, 108707.	6.4	16
256	Tumor and Tumor-Associated Macrophage Programmed Death-Ligand 1 Expression Is Associated With Adjuvant Chemotherapy Benefit in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2022, 17, 89-102.	1.1	16
257	Primary myoepithelial carcinoma of the lung: a rare entity treated with parenchymal sparing resection. Journal of Cardiothoracic Surgery, 2011, 6, 27.	1.1	15
258	Megakaryoblastic transformation of chronic granulocytic leukemia. Cancer, 1987, 60, 193-200.	4.1	14
259	Spread Through Air Spaces (STAS) in Nonâ˜Small Cell Lung Carcinoma. American Journal of Surgical Pathology, 2021, 45, 1509-1515.	3.7	14
260	Algorithmic Approach to the Diagnosis of Organizing Pneumonia. Chest, 2022, 162, 156-178.	0.8	13
261	Editorial Comment: Recent advances in our understanding of lung cancer visceral pleural invasion and other forms of minimal invasion: implications for the next TNM classification. European Journal of Cardio-thoracic Surgery, 2013, 43, 309-311.	1.4	12
262	State of the Art: Toward Improving Outcomes of Lung and Liver Tumor Biopsies in Clinical Trialsâ€”A Multidisciplinary Approach. Journal of Clinical Oncology, 2020, 38, 1633-1640.	1.6	12
263	Updated Protocol for the Examination of Specimens From Patients With Carcinoma of the Lung. Archives of Pathology and Laboratory Medicine, 2003, 127, 1304-1313.	2.5	12
264	The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: Unresolved Issues to be Addressed for the Next Ninth Edition of the TNM Classification of Malignant Tumors. Journal of Thoracic Oncology, 2022, 17, 838-851.	1.1	12
265	Endotracheal Myoepithelioma. Chest, 2011, 140, 242-244.	0.8	11
266	Tumoral CD10 expression correlates with high-grade histology and increases risk of recurrence in patients with stage I lung adenocarcinoma. Lung Cancer, 2015, 89, 329-336.	2.0	11
267	Neuroendocrine Lung Tumors. , 2006, 11, 235-242.		10
268	Node Doubt: Rigorous Surgical Nodal Procurement Combined With Thorough Pathologic Evaluation Improves Non-Small Cell Lung Carcinoma Staging Accuracy. Annals of Thoracic Surgery, 2016, 102, 353-356.	1.3	10
269	Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations. Journal of Thoracic Oncology, 2019, 14, 1989-1994.	1.1	10
270	Intentional Segmentectomy for Clinical T1 N0 Non-small Cell Lung Cancer: Survival Differs by Segment. Annals of Thoracic Surgery, 2021, 111, 1028-1035.	1.3	10

#	Article	IF	Citations
271	The Ki-67 antigen in the new 2021 World Health Organization classification of lung neuroendocrine neoplasms. Pathologica, 2021, 113, 377-387.	3.4	10
272	Tumoral CD10 Expression Correlates with Aggressive Histology and Prognosis in Patients with Malignant Pleural Mesothelioma. Annals of Surgical Oncology, 2015, 22, 3136-3143.	1.5	9
273	Identification and Functional Characterization of EGFR V769M, a Novel Germline Variant Associated With Multiple Lung Adenocarcinomas. JCO Precision Oncology, 2017, 1, 1-10.	3.0	9
274	Can IASLC/ATS/ERS subtype help predict response to chemotherapy in small biopsies of advanced lung adenocarcinoma?. European Respiratory Journal, 2014, 43, 1240-1242.	6.7	8
275	The International Association for the Study of Lung Cancer Molecular Database Project: Objectives, Challenges, and Opportunities. Journal of Thoracic Oncology, 2021, 16, 897-901.	1.1	8
276	Preponderance of High-Grade Histologic Subtype in Autologous Metastases in Lung Adenocarcinoma. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 816-818.	5.6	7
277	Forty Years of the International Association for Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 2014, 9, 1740-1749.	1.1	6
278	Spread Through Air Spaces Is Prognostic in Neuroendocrine Lung Tumors and Can Be Distinguished From Artifacts. Journal of Thoracic Oncology, 2020, 15, e118-e120.	1.1	6
279	Pathologic Assessment of Lung Squamous Cell Carcinoma After Neoadjuvant Immunotherapy. Journal of Thoracic Oncology, 2021, 16, e9-e10.	1.1	6
280	NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell Carcinoma. Journal of Thoracic Oncology, 2022, 17, 793-805.	1.1	6
281	The tumor immune microenvironment in octogenarians with stage I non-small cell lung cancer. OncoImmunology, 2014, 3, e967142.	4.6	5
282	The Newly Described Filigree Pattern Is an Expansion of the Micropapillary Adenocarcinoma Concept Rather Than a Proposed New Subtype. Journal of Thoracic Oncology, 2020, 15, e121-e124.	1.1	5
283	Immune checkpoint inhibitorâ€related pneumonitis: Acute lung injury with rapid progression and organizing pneumonia with less severe clinical disease. Histopathology, 0, , .	2.9	4
284	Surgical Lung Biopsy in the Diagnosis of Idiopathic NSIP: Do We Always Need It in the Initial Approach?. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 1071-1072.	5.6	3
285	Diagnostic criteria for idiopathic pulmonary fibrosis â€“ Authorsâ€™ reply. Lancet Respiratory Medicine,the, 2018, 6, e7.	10.7	3
286	Predicting spread through air spaces (STAS) preoperatively: can imaging help?. Journal of Thoracic Disease, 2019, 11, S1938-S1941.	1.4	3
287	Molecular differences across invasive lung adenocarcinoma morphological subgroups. Translational Lung Cancer Research, 2020, 9, 1029-1040.	2.8	3
288	Prognostic Impact of Ground-Glass Opacity/Lepidic Component in Pulmonary Adenocarcinoma: A Hazy Staging Dilemma. Journal of Thoracic Oncology, 2022, 17, 19-21.	1.1	3

#	Article	IF	Citations
289	Reprint of â€œIntroduction to 2021 WHO Classification of Thoracic Tumorsâ€. Journal of Thoracic Oncology, 2022, 17, 337-340.	1.1	3
290	Editorial Comment: Clinical relevance and TNM implications of the new concept of minimally-invasive adenocarcinomas in situ with a lepidic pattern. European Journal of Cardio-thoracic Surgery, 2013, 43, 932-933.	1.4	2
291	Diagnosis of Hypersensitivity Pneumonitis. American Journal of Surgical Pathology, 2021, Publish Ahead of Print, .	3.7	2
292	Large Cell Neuroendocrine Carcinoma. , 2006, , 298-306.		1
293	Understanding Nonspecific Interstitial Pneumonia: The Need for a Diagnostic Gold Standard. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 256-256.	5.6	1
294	Type A thymoma presenting with bone metastasis. Histopathology, 2018, 73, 701-703.	2.9	1
295	E12-01: NCI Director's challenge gene profiling of lung adenocarcinomas: impact on histologic classification. Journal of Thoracic Oncology, 2007, 2, S254-S256.	1.1	1
296	Interstitial lung disease. Diagnostic Histopathology, 2008, 14, 499-508.	0.4	0
297	Histologic Classification and Its Need for Treatment of Lung Cancer. , 2015, , 1-14.		0
298	Lung Cancer Pathology Blueprint for Future Work. Japanese Journal of Lung Cancer, 2007, 47, 903-903.	0.1	0
299	Pulmonary Pathology Society Lifetime Achievement Award, 2007: Raymond Yesner, MD, Professor of Pathology Emeritus, Yale University School of Medicine. Archives of Pathology and Laboratory Medicine, 2007, 131, 1634-1634.	2.5	0
300	Lung Pathology. , 2009, , 71-87.		0
301	Endocrine Lung. , 2010, , 429-445.		0
302	Atypical Pathogens Presenting With Pulmonary Consolidations Detected by Cell-Free DNA Next-Generation Sequencing in Patients With Hematologic Malignancies. Infectious Diseases in Clinical Practice, 2022, 30, .	0.3	0